



## Lipomics Receives Department of Defense Grant for Study Using Lipid Analysis to Assess Fitness

*Study results to help predict fitness and endurance of combat personnel*

WEST SACRAMENTO, California, Oct. 25, 2004 -- Lipomics Technologies, Inc., a privately held company that specializes in lipid metabolite analysis and interpretation, today announced that it has received a Small Business Technology Transfer (STTR) Grant from the Department of Defense (DOD) for a two-phase study to help assess and ultimately improve the optimum fitness and performance of combat personnel.

Collaborating with the University of California, Davis, and Arête Therapeutics, Inc., the first phase of the study will employ previously developed and validated metabolomic analysis platforms to study how metabolic profiles can predict performance, metabolic stress, fatigue and recovery rates for individuals undergoing extreme exertion.

The specific aim of the study is to analyze and profile structural changes in plasma metabolites that may indicate tissue or metabolic changes. The study will also seek evidence of physiological stress during strenuous physical activity by measurement of eicosanoids, hormone-like substances produced in the body that can indicate possible compromise to the immune system. The study findings will be used to develop analytical tools to identify biomarkers of physical readiness, and markers that will predict potential damage in individual soldiers during times of physical stress. Accurate measurements of an individual soldier's metabolic profile will also help improve training regimens, dietary guidance and if necessary, therapeutic intervention to optimize their preparedness prior to and recovery after exhaustive activity.

### About Lipomics Technologies, Inc.

Lipomics develops tools for drug discovery and personalized medicine using proprietary technologies for lipid metabolism analysis and data interpretation. We generate a comprehensive understanding of lipid metabolism from plasma, serum or tissue samples by combining quantitative measurements of lipid metabolites with proprietary algorithms for mapping the lipomic profiles to biochemical pathways. In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technology to speed drug discovery processes, improve clinical trial stratification, reduce late-stage drug attrition, discover new biomarkers and develop early tests for monitoring drug response. More information about Lipomics can be found at [www.lipomics.com](http://www.lipomics.com).

EDITORIAL CONTACTS:

Sarina Chohan  
(916) 371-7974

[schohan@lipomics.com](mailto:schohan@lipomics.com)

Media Contact

Doug Forsyth, Alchymia Communications  
(541) 482-8744

[df@alchymiacomm.com](mailto:df@alchymiacomm.com)